SUR receptor activity vs. incidence of hypoglycaemia and cardiovascular mortality with sulphonylurea therapy for diabetics

Diabetes, Obesity and Metabolism

Volumn 10, Issue 11, 2008, Pages 1128-1129

  Tayek, J ^a  

^a HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROPAMIDE; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; HEMOGLOBIN A1C; METFORMIN; PIOGLITAZONE; PLACEBO; SULFONYLUREA DERIVATIVE; SULFONYLUREA RECEPTOR; SULFONYLUREA RECEPTOR 2; TOLBUTAMIDE; UNCLASSIFIED DRUG;

ANGINA PECTORIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC PATIENT; DRUG MECHANISM; DRUG RECEPTOR BINDING; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; LETTER; MONOTHERAPY; MORTALITY; RISK ASSESSMENT; SIDE EFFECT; ST SEGMENT DEPRESSION;

EID: 54249106759     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2008.00928.x     Document Type: Letter

References (12)

1. Evans JMM, Ogston SA, Reimann F, Gribble FM, Morris AD, Pearson ER. No differences in mortality between users of pancreatic-specific and non-pancreatic-specific sulphonylureas: A cohort analysis. Diabetes Obes Metab 2008; 10: 350-352 doi:10.1111/j.1463-1326.2007.00833.x.
2. ACCORD. Effects of Intensive Glucose Lowering in Type 2 Diabetes. New England Journal of Medicine 2008; 358: 2545-2559.
3. Szoke N, Gosmanov J, Sinkin A et al. Effects of glimepiride and glyburide on glucose counterregulation and recovery from hypoglycemia. Metabolism 2006; 55: 78-83.
4. Hellman B, Sehlin J, Täljedal IB. Glibenclamide is exceptional among hypoglycaemic sulphonylureas in accumulating progressively in beta-cell-rich pancreatic islets. Acta Endocrinol (Copenh) 1984; 105: 385-390.
5. Jain R, Osei K, Kupfer S, Perez AT, Zhang J. Long-term safety of pioglitazone versus glyburide in patients with recently diagnosed type 2 diabetes mellitus. Pharmacotherapy 2006; 26: 1388-1395.
6. Goldner MG, Knatterud GL, Prout TE, for the University Group Diabetes Program. Effects of hypoglycemia agents on vascular complications in patients with adult-onset diabetes. JAMA 1971; 218: 1400-1410.
7. Gangji AS, Cukierman T, Gerstein HC, Goldsmith CH, Clase MD. A systematic review and meta-analysis of hypoglycemia and cardiovascular events: A comparison of glyburide with other secretagogues and with insulin. Diabetes Care 2007; 30: 389-394.
8. Holstein A, Plaschke A. Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes Metab Res Rev 2001; 17: 467-473.
9. Stahl M, Berger W. Higher incidence of severe hypoglycaemia leading to hospital admission in type 2 diabetic patients treated with long-acting versus short-acting sulphonylureas. Diabet Med 1999; 16: 586-590.
10. Holstein A, Egberts EH. Risk of hypoglycaemia with oral antidiabetic agents in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes 2003; 111: 405-414.
11. Klepzig H, Kober G, Matter C et al. Sulfonylureas and ischaemic preconditioning a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide. Eur Heart J 1999; 20: 439-446.
12. Monami M, Luzzi C, Lamanna C et al. Three-year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin. Diabetes Metab Res Rev 2006; 22: 477-482.